Why Humacyte Stock Is Trading 15% Higher Monday
Why Humacyte Stock Is Trading 15% Higher Monday
Humacyte's ATEV is a implantable conduit designed for blood vessel replacement and repair. It showed low infection rates in clinical trials and it is available off-the-shelf for immediate use by surgeons. The novel treatment is beneficial for PAD patients who may not have suitable veins for standard lower leg bypass procedures.Humacyte, Inc. (NASDAQ:HUMA) is moving higher on Monday after receiving the Food and Drug Administration's Regenerative Medicine Advanced Therapy (RMAT) designation for its Acellular Tissue Engineered Vessel (ATEV).
纳斯达克股票代码为HUMA的Humacyte公司周一上涨，因其无细胞组织工程血管（ATEV）获得美国食品和药物管理局的再生医学先进疗法（RMAT）认定。
What To Know: This is the biotechnology company's third time receiving the RMAT designation which is designed to expedite the development and review of therapies for serious conditions.
需要了解的事项：这家生物技术公司已经第三次获得RMAT认证，该认证旨在加快严重疾病疗法的开发和审查。
The designation was specifically granted for the use of ATEV for patients with Advanced Peripheral Artery Disease (PAD).
认定是专门针对PAD晚期患者使用ATEV的。
Humacyte's ATEV is a implantable conduit designed for blood vessel replacement and repair. It showed low infection rates in clinical trials and it is available off-the-shelf for immediate use by surgeons. The novel treatment is beneficial for PAD patients who may not have suitable veins for standard lower leg bypass procedures.
Humacyte的ATEV是一种可植入的导管，设计用于血管置换和修复。它在临床试验中显示出低感染率，并可随时供外科医生使用。这种新型治疗对于可能没有适合标准下肢搭桥手术的PAD患者非常有益。
"We are excited that this additional designation has been granted in advanced PAD, as we expect that it will further strengthen our communication with the FDA and expedite the development of our ATEV in this important indication," said Dr. Cindy Cao, chief regulatory officer at Humacyte.
Humacyte首席监管官Cindy Cao博士表示：“我们很高兴在PAD晚期获得了这一额外的认定，因为我们预计这将进一步加强我们与FDA的沟通，并加速我们ATEV在这一重要适 indication的开发。”
Related Link: Why Complete Solaria Stock Is Rising
相关链接：为什么Complete Solaria的股票正在上涨
HUMA Price Action: Humacyte stock is trading 15% higher at $5.52 at the time of writing per data from Benzinga Pro.
HUMA价格行动：根据Benzinga Pro的数据，Humacyte股票在撰写时以5.52美元的价格上涨了15％。
Image: Photo Via Shutterstock
图像：通过shutterstock的照片
